Amylyx Pharmaceuticals Assesses ALS Trial Setback and Future Steps

Amylyx Pharmaceuticals Inc (AMLX) has provided an announcement.

Amylyx Pharmaceuticals reported disappointing results from its PHOENIX Phase 3 trial of AMX0035 for ALS, failing to meet primary and secondary endpoints. Despite the setback, the company will continue to provide the drug and support to ALS patients. They also plan to discuss the trial outcomes with regulatory authorities and the ALS community. Meanwhile, Amylyx is pausing the drug’s promotion and may consider withdrawing it from the market. Separate ongoing studies for AMX0035 in other neurodegenerative diseases, such as PSP and Wolfram syndrome, are still in progress, with results expected in the coming years.

See more data about AMLX stock on TipRanks’ Stock Analysis page.